Fundraising Fox

Cambrian Bio

Delaware corporation · 7 known investors

cambrianbio.com ↗

Cambrian Bio is a clinical-stage biopharmaceutical company developing precision therapeutics targeting metabolic pathways associated with aging, including AMPK and mTOR. Its lead asset, ATX-304, is the first AMPK Network Activator in clinical development for obesity and prediabetes.

BiotechLongevityMedical Devicesin /cambrianbio

Founders & leadership

JG
James G. PeyerExecutive Officer, Director
JH
Juliette HanExecutive Officer, Director
MN
Mark NuttallExecutive Officer
RT
Ruth Thieroff-EkerdtExecutive Officer
WD
William DeVaulExecutive Officer
CA
Christian AngermeyerDirector
BL
Brenton L. SaundersDirector
MG
Martin GunhagaDirector
LV
Lorin Van NulandDirector
CA
Christian AngermayerDirector
MS
Maryanna SaenkoDirector
PF
Paul FarrDirector

Investors · 7

Catalio Capital Management, LPNew York
Future VenturesLos Altos · $1M – $10M
Khosla VenturesMenlo Park · $5K – $50M
Korify Capital
Sprint VcBangalore · $300
Strawberry Creek VenturesManchester
atai Life SciencesreportedNew Yorkvia Christian Angermayer · board

Reported raises · per SEC filings

Form D private placements
▶$123.8MraisedJul 2026 · 80 investors · Biotechnology
Rule 506(c)
Officers, directors & promoters on the filing
  • James PeyerExecutive Officer, Director
  • Juliette HanExecutive Officer, Director
  • Mark NuttallExecutive Officer
  • Ruth Thieroff-EkerdtExecutive Officer
  • William DeVaulExecutive Officer
  • Christian AngermeyerDirector
  • Maryanna SaenkoDirector
  • Brenton L. SaundersDirector
  • Paul FarrDirector
  • Martin GunhagaDirector
  • Lorin Van NulandDirector
Offering amount
$129.8M
Amount sold
$123.8M
First sale
Jun 2026
Incorporated
Corporation, Delaware
Federal exemptions
06c
Full filing on SEC EDGAR ↗
▶$23MraisedJan 2025 · 30 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Christian AngermayerDirector
  • Maryanna SaenkoDirector
  • Paul FarrDirector
  • James G. PeyerExecutive Officer, Director
  • Brenton SaundersDirector
Offering amount
$37.6M
Amount sold
$23M
First sale
Jun 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$92.2MraisedDec 2021 · 56 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Christian AngermayerDirector
  • Maryanna SaenkoDirector
  • James G. PeyerExecutive Officer, Director, Promoter
Offering amount
$100.8M
Amount sold
$92.2M
First sale
Oct 2021
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$28.4MraisedMay 2021 · 30 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • James G. PeyerExecutive Officer, Director, Promoter
  • Christian AngermeyerDirector
  • Maryanna SaenkoDirector
Offering amount
$28.4M
Amount sold
$28.4M
First sale
Oct 2020
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.8MraisedJan 2020 · 5 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Christian AngermeyerDirector
  • James G. PeyerExecutive Officer, Director, Promoter
Offering amount
$4.8M
Amount sold
$4.8M
First sale
Oct 2019
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.